Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
about
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewOptions for empagliflozin in combination therapy in type 2 diabetes mellitusDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsComparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysisPractical combination therapy based on pathophysiology of type 2 diabetesImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureNew and emerging drugs and targets for type 2 diabetes: reviewing the evidenceBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsToe amputations with SGLT-2 inhibitors: data from randomized clinical trials.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesEmpagliflozin in the treatment of type 2 diabetes: evidence to dateEfficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsEffect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trialsShort commentary on empagliflozin and its potential clinical impactThe role of empagliflozin in the management of type 2 diabetes by patient profile.Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusEmpagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisPopulation Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.
P2860
Q24563917-2F481A13-6EBB-4BF4-B288-9BE5896D7531Q26745771-DC49F197-DBA3-43DA-B489-231B6D5DAD72Q26749281-1A2839F7-D4AC-4C2D-A2E1-CE79C9428F69Q26864336-BECD7857-2A21-4961-B9A5-E20A3BEC67CCQ27301948-FFEB85F1-3123-40FA-BADE-C39238B3D702Q28072765-FB7C4323-4516-4B2B-9317-1937EAE31918Q28074573-5D889B13-508B-4FCE-8067-D9D4A15FDEC5Q28076530-72572EDE-D97D-4DF8-938C-2CFE4CA13B1AQ28080114-25F43972-E1C7-4B59-A666-A5CB88D222E9Q28085516-02C906BB-0220-4A2F-9FB9-FD750E7CFEE2Q28553482-C8612F54-3E56-4772-923B-6C1D66245D1AQ30248634-6DE0D1B2-45C7-4A23-9C71-2989E6D1C6C5Q30249371-9667882C-770D-46FA-9B8C-D12013C4062BQ30903369-D849C5ED-F0E8-4174-8A27-A7968D5131C5Q31105792-B8994ED8-5D0B-4BF4-8B71-23D487980466Q31112303-6A114AE2-6790-4E14-982D-624E7653C2C7Q31138508-46941C9B-56B1-4AC6-B68C-FD9314755912Q32186373-5FF8D77A-D7E5-4470-B1C3-FB82406C7BE8Q33812170-EFC9C6B1-244A-40E9-A3D1-EE37C9E04156Q33837017-5DB28BBF-807F-4C6C-A7C9-9E9B56935AB1Q33857698-C9BC1323-4A40-4333-AB98-8CFD99126BCDQ33885732-A759C1CA-C557-4DA8-BDA6-F6C623E6C15DQ33890770-4751E62C-106B-49A2-8595-DB73D8314C33Q34198692-DA04CAA7-DADD-41C1-9EF3-B4D6B4AE4153Q34502358-0A72D273-E775-4908-81F7-4695CFA7F12AQ34543009-9E71FD9D-A2FD-4F0F-9D41-BB2B39561E29Q34973750-3DD5BFAF-9157-41FB-96F1-246F5AE27070Q35117192-DD08987E-4F70-4081-BEA4-87CF8F84D48BQ35157497-E05050EF-CA0B-4390-8668-243F7E4E7EEBQ35260544-69BDFADD-8C8A-459A-99A1-D95D90618A43Q35528797-5CBD8165-2154-42A2-9232-8C01231E7890Q35592873-A7897C6E-6A80-4732-90FF-6D09CB001C45Q35831426-DBF8BCDA-2CE1-4DCE-AE66-93E4CA7C15D3Q36402095-CF193B0E-7FAF-4E8B-8810-95ADB2A5F9A9Q36555418-7BF5127A-A477-4B7C-A445-D1AE07CC842DQ36592820-A2EB5AB3-0D4A-413B-83F2-8D6F409B0576Q36622125-15A066FF-0BEA-4008-98CB-84614D466514Q36960633-17C31AFC-2309-4B1A-A1E5-714022820E67Q37030680-59184B30-FC6E-4FA9-8B36-F42A258FFC4FQ37239278-BD42EF69-4BFC-4E75-B4F5-2B673235411A
P2860
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Empagliflozin improves glycaem ...... zed, placebo-controlled trial.
@en
Empagliflozin improves glycaem ...... zed, placebo-controlled trial.
@nl
type
label
Empagliflozin improves glycaem ...... zed, placebo-controlled trial.
@en
Empagliflozin improves glycaem ...... zed, placebo-controlled trial.
@nl
prefLabel
Empagliflozin improves glycaem ...... zed, placebo-controlled trial.
@en
Empagliflozin improves glycaem ...... zed, placebo-controlled trial.
@nl
P2093
P2860
P921
P356
P1476
Empagliflozin improves glycaem ...... zed, placebo-controlled trial.
@en
P2093
EMPA-REG PIO™ trial investigators
H J Woerle
H Rattunde
U C Broedl
P2860
P304
P356
10.1111/DOM.12188
P577
2013-08-22T00:00:00Z